Role of the N- and C-terminal fragments of parathyroid-hormone-related protein as putative therapies to improve bone regeneration under high glucocorticoid treatment

Tissue Engineering - Part A

Volumn 16, Issue 4, 2010, Pages 1157-1168

  De Castro, Luís Fernándes ^a   Lozano, Daniel ^a   Dapía, Sonia ^b   Portal Núñez, Sergio ^a   Caeiro, José R ^b   Gómez Barrena, Enrique ^c   Esbrit, Pedro ^a  

^a Bone and Mineral Metab Laboratory   (Spain)

^b Trabeculae   (Spain)

^c UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ABLATION; MAMMALS; PEPTIDES; TOMOGRAPHY;

ADIPOCYTES; BONE DISEASE; BONE FORMATION; BONE MARROW; BONE REGENERATION; BONE REMODELING; BONE STRUCTURE; C-TERMINAL FRAGMENTS; MICRO-COMPUTERIZED TOMOGRAPHY; OSTEOBLASTIC CELLS; OSTEOCYTES; OSTEOGENESIS; SCLEROSTIN; VASCULARIZATION;

BONE;

ANIMALIA; MUS;

BONE MORPHOGENETIC PROTEIN; METHYLPREDNISOLONE; PARATHYROID HORMONE RELATED PEPTIDE (1 36); PARATHYROID HORMONE RELATED PROTEIN; PARATHYROID HORMONE RELATED PROTEIN (107 139); PARATHYROID HORMONE-RELATED PEPTIDE (1-36); PARATHYROID HORMONE-RELATED PROTEIN (107-139); PEPTIDE FRAGMENT; SOST PROTEIN, MOUSE;

ANIMAL; ARTICLE; BONE DENSITY; BONE DEVELOPMENT; BONE REGENERATION; C57BL MOUSE; CELL CULTURE; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; GENETIC MARKER; MALE; METABOLISM; MICRO-COMPUTED TOMOGRAPHY; MOUSE; OSTEOLYSIS; PHYSIOLOGY; RADIOGRAPHY; TIBIA; TISSUE ENGINEERING;

ANIMALS; BONE DENSITY; BONE MORPHOGENETIC PROTEINS; BONE REGENERATION; BONE RESORPTION; CELLS, CULTURED; GENETIC MARKERS; MALE; METHYLPREDNISOLONE; MICE; MICE, INBRED C57BL; OSTEOGENESIS; PARATHYROID HORMONE-RELATED PROTEIN; PEPTIDE FRAGMENTS; TIBIA; TISSUE ENGINEERING; X-RAY MICROTOMOGRAPHY;

EID: 77950816743     PISSN: 19373341     EISSN: 1937335X     Source Type: Journal    
DOI: 10.1089/ten.tea.2009.0355     Document Type: Article

References (57)

1. Bisello, A., Horwitz, M.J., and Stewart, A.F. Parathyroid hormone-related protein: an essential physiological regulator of adult bone mass. Endocrinology 145, 3551, 2004.
2. Miao, D., He, B., Jiang, Y., Kobayashi, T., Sorocéanu, M.A., Zhao, J., Su, H., Tong, X., Amizuka, N., Gupta, A., Genant, H.K., Kronenberg, H.M., Goltzman, D., and Karaplis, A.C. Osteoblast-derived PTHrP is a potent endogenous bone anabolic agent that modifies the therapeutic efficacy of administered PTH 1-34. J Clin Invest 115, 2402, 2005.
3. Mart́nez, P., Esbrit, P., Rodrigo, A., Alvarez-Arroyo, M.V., and Mart́nez, M.E. Age-related changes in parathyroid hormone-related protein and vascular endothelial growth factor in human osteoblastic cells. Osteoporos Int 13, 874, 2002.
4. Lozano, D., de Castro, L.F., Dapéa, S., Andrade-Zapata, I., Manzarbeitia, F., Alvarez-Arroyo, M.V., Gómez-Barrena, E., and Esbrit, P. Role of parathyroid hormone-related protein in the decreased osteoblast function in diabetes-related osteopenia. Endocrinology 150, 2027, 2009.
5. Rouffet, J., Coxam, V., Gaumet, N., and Barlet, J.P. Preserved bone mass in ovariectomized rats treated with parathyroidhormone-related peptide (1-34) and (107-111) fragments. Reprod Nutr Dev 34, 473, 1994.
6. Stewart, A.F., Cain, R.L., Burr, D.B., Jacob, D., Turner, C.H., and Hock, J.M. Six-month daily administration of parathyroid hormone and parathyroid hormone-related protein peptides to adult ovariectomized rats markedly enhances bone mass and biomechanical properties: a comparison of human parathyroid hormone 1-34, parathyroid hormonerelated protein 1-36, and SDZ-parathyroid hormone 893. J Bone Miner Res 15, 1517, 2000.
7. Horwitz, M.J., Tedesco, M.B., Gundberg, C., Garcia-Ocaña, A., and Stewart, A.F. Short-term, high-dose parathyroid hormone-related protein as a skeletal anabolic agent for the treatment of postmenopausal osteoporosis. J Clin Endocrinol Metab 88, 569, 2003.
8. Fenton, A.J., Kemp, B.E., Kent, G.N., Moseley, J.M., Zheng, M.H., Rowe, D.J., Britto, J.M., Martin, T.J., and Nicholson, G.C. A carboxyl-terminal peptide from the parathyroid hormone-related protein inhibits bone resorption by osteoclasts. Endocrinology 129, 1762, 1991.
9. Rihani-Basharat, S., and Lewinson, D. PTHrP(107-111) inhibits in vivo resorption that was stimulated by PTHrP(1-34) when applied intermittently to neonatal mice. Calcif Tissue Int 61, 426, 1997.
10. Cornish, J., Callon, K.E., Nicholson, G.C., and Reid, I.R. Parathyroid hormone-related protein-(107-139) inhibits bone resorption in vivo. Endocrinology 138, 1299, 1997.
11. Cornish, J., Callon, K.E., Lin, C., Xiao, C., Moseley, J.M., and Reid, I.R. Stimulation of osteoblast proliferation by Cterminal fragments of parathyroid hormone-related protein. J Bone Miner Res 14, 915, 1999.
12. de Gortázar, A.R., Alonso, V., Alvarez-Arroyo, M.V., and Esbrit, P. Transient exposure to PTHrP (107-139) exerts anabolic effects through vascular endothelial growth factor receptor 2 in human osteoblastic cells in vitro. Calcif Tissue Int 79, 360, 2006.
13. Alonso, V., de Gortázar, A.R., Ardura, J.A., Andrade-Zapata, I., Alvarez-Arroyo, M.V., and Esbrit, P. Parathyroid hormonerelated protein (107-139) increases human osteoblastic cell survival by activation of vascular endothelial growth factor receptor-2. J Cell Physiol 217, 717, 2008.
14. Towler, D.A. Vascular biology and bone formation: hints from HIF. J Clin Invest 117, 1477, 2007.
15. Clowes, J.A., Peel, N., and Eastell, R. Glucocorticoid-induced osteoporosis. Curr Opin Rheumatol 13, 326, 2001.
16. Rubin, M.R., and Bilezikian, J.P. Clinical review 151: The role of parathyroid hormone in the pathogenesis of glucocorticoid-induced osteoporosis: a re-examination of the evidence. J Clin Endocrinol Metab 87, 4033, 2002.
17. Jia, D., O'Brien, C.A., Jia, D., O'Brien, C.A., Stewart, S.A., Manolagas, S.C., and Weinstein, R.S. Glucocorticoids act directly on osteoclasts to increase their life span and reduce bone density. Endocrinology 147, 5592, 2006.
18. Hofbauer, L.C., Gori, F., Riggs, B.L., Lacey, D.L., Dunstan, C.R., Spelsberg, T.C., and Khosla, S. Stimulation of osteo-protegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocorticoidinduced osteoporosis. Endocrinology 140, 4382, 1999.
19. Kim, H.J., Zhao, H., Kitaura, H., Bhattacharyya, S., Brewer, J.A., Muglia, L.J., Ross, F.P., and Teitelbaum, S.L. Glucocorticoids suppress bone formation via the osteoclast. J Clin Invest 116, 2152, 2006.
20. Weinstein, R.S., Jilka, R.L., Parfitt, A.M., and Manolagas, S.C. Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. J Clin Invest 102, 274, 1998.
21. O'Brien, C.A., Jia, D., Plotkin, L.I., Bellido, T., Powers, C.C., Stewart, S.A., Manolagas, S.C., and Weinstein, R.S. Glucocorticoids act directly on osteoblasts and osteocytes to induce their apoptosis and reduce bone formation and strength. Endocrinology 145, 1835, 2004.
22. Ishida, Y., and Heersche, J.N.M. Glucocorticoid-induced osteoporosis: both in vivo and in vitro concentrations of glucocorticoids higher than physiological levels attenuate osteoblast differentiation. J Bone Miner Res 12, 1822, 1998.
23. Walsh, C.A., Birch, M.A., Fraser, W.D., Lawton, R., Dorgan, J., Walsh, S., Sansom, D., Beresford, J.N., and Gallagher, J.A. Expression and secretion of parathyroid hormone-related protein by human bone-derived cells in vitro: effects of glucocorticoids. J Bone Miner Res 10, 17, 1995.
24. Hömme, M., Schmitt, C.P., Himmele, R., Hoffmann, G.F., Mehls, O., and Schaefer, F. Vitamin D and dexamethasone inversely regulate parathyroid hormone-induced regulator of G protein signaling-2 expression in osteoblast-like cells. Endocrinology 144, 2496, 2003.
25. Ureña, P., Iida-Klein, A., Kong, X.F., Jüppner, H., Kronenberg, H.M., Abou-Samra, A.B., and Segre, G.V. Regulation of parathyroid hormone (PTH)=PTH-related peptide receptor messenger ribonucleic acid by glucocorticoids and PTH in ROS 17=2.8 and OK cells. Endocrinology 134, 451, 1994.
26. Ahlström, M., Pekkinen, M., and Lamberg-Allardt, C. Dexamethasone downregulates the expression of parathyroid hormone-related protein (PTHrP) in mesenchymal stem cells. Steroids 74, 277, 2009.
27. Yao, W., Cheng, Z., Pham, A., Busse, C., Zimmermann, E.A., Ritchie, R.O., and Lane,N.E. Glucocorticoid-induced bone loss in mice can be reversed by the actions of parathyroid hormone and risedronate on different pathways for bone formation and mineralization. Arthritis Rheum 58, 3485, 2008.
28. Saag, K.G., Shane, E., Boonen, S., Marén, F., Donley, D.W., Taylor, K.A., Dalsky, G.P., and Marcus, R. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med 357, 2028, 2007.
29. Kondo, N., Tokunaga, K., Ito, T., Arai, K., Amizuka, N., Minqi, L., Kitahara, H., Ito, M., Naito, M., Shu-Ying, J., Oda, K., Murai, T., Takano, R., Ogose, A., and Endo, N. High dose glucocorticoid hampers bone formation and resorption after bone marrow ablation in rat. Microsc Res Tech 69, 839, 2006.
30. Ho, M.L., Chang, J.K., and Wang, G.J. Antiinflammatory drug effects on bone repair and remodeling in rabbits. Clin Orthop Relat Res 313, 270, 1995.
31. Zhang, Q., Cuartas, E., Mehta, N., Gilligan, J., Ke, H.Z., Saltzman, W.M., Kotas, M., Ma, M., Rajan, S., Chalouni, C., Carlson, J., and Vignery, A. Replacement of bone marrow by bone in rat femurs: the bone bioreactor. Tissue Eng A 14, 237, 2008.
32. Frey, F.J. Kinetics and dynamics of prednisolone. Endocr Rev 8, 453, 1987.
33. McLaughlin, F., Mackintosh, J., Hayes, B.P., McLaren, A., Uings, I.J., Salmon, P., Humphreys, J., Meldrum, E., and Farrow, S.N. Glucocorticoid-induced osteopenia in the mouse as assessed by histomorphometry, microcomputed tomography, and biochemical markers. Bone 30, 924, 2002.
34. Weinstein, R.S., Chen, J.R., Powers, C.C., Stewart, S.A., Landes, R.D., Bellido, T., Jilka, R.L., Parfitt, A.M., and Manolagas, S.C. Promotion of osteoclast survival and antagonism of bisphosphonate-induced osteoclast apoptosis by glucocorticoids. J Clin Invest 109, 1041, 2002.
35. Mattsson, G., Carlsson, P.O., Olausson, K., and Jansson, L. Histological markers for endothelial cells in endogenous and transplanted rodent pancreatic islets. Pancreatology 2, 155, 2002.
36. Shirata, K., Suzuki, T., Yanaihara, N., Sugimoto, K., and Mori, K.J. Establishment of a sarcoma cell line, MS-K, expressing Ki-ras proto-oncogene product from mouse bone marrow stromal cells. Biomed Pharmacother 45, 1, 1991.
37. Redlich, K., Hayer, S., Ricci, R., David, J.P., Tohidast-Akrad, M., Kollias, G., Steiner, G., Smolen, J.S., Wagner, E.F., and Schett, G. Osteoclasts are essential for TNF-alpha-mediated joint destruction. J Clin Invest 110, 1419, 2002.
38. Ikeda, T., Kasai, M., Suzuki, J., Kuroyama, H., Seki, S., Utsuyama, M., and Hirokawa, K. Multimerization of the receptor activator of nuclear factor-kappaB ligand (RANKL) isoforms and regulation of osteoclastogenesis. J Biol Chem 278, 47217, 2003.
39. Wada, S., Yasuda, S., Nagai, T., Maeda, T., Kitahama, S., Suda, S., Findlay, D.M., Iitaka, M., and Katayama, S. Regulation of calcitonin receptor by glucocorticoid in human osteoclast-like cells prepared in vitro using receptor activator of nuclear factor-kappaB ligand and macrophage colonystimulating factor. Endocrinology 142, 1471, 2001.
40. Kim, Y.H., Jun, J.H., Woo, K.M., Ryoo, H.M., Kim, G.S., and Baek, J.H. Dexamethasone inhibits the formation of multinucleated osteoclasts via down-regulation of beta3 integrin expression. Arch Pharm Res 29, 691, 2006.
41. O'Brien, C.A., Plotkin, L.I., Galli, C., Goellner, J.J., Gortázar, A.R., Allen, M.R., Robling, A.G., Bouxsein, M., Schipani, E., Turner, C.H., Jilka, R.L., Weinstein, R.S., Manolagas, S.C., and Bellido, T. Control of bone mass and remodeling by PTH receptor signaling in osteocytes. PLoS ONE 3, e2942, 2008.
42. Shimizu, T., Mehdi, R., Yoshimura, Y., Yoshikawa, H., Nomura, S., Miyazono, K., and Takaoka, K. Sequential expression of bone morphogenetic protein, tumor necrosis factor, and their receptors in bone-forming reaction after mouse femoral marrow ablation. Bone 23, 127, 1998.
43. Vaes, B.L., Ducy, P., Sijbers, A.M., Hendriks, J.M., van Someren, E.P., de Jong, N.G., van den Heuvel, E.R., Olijve, W., van Zoelen, E.J., and Dechering, K.J. Microarray analysis on Runx2-deficient mouse embryos reveals novel Runx2 functions and target genes during intramembranous and endochondral bone formation. Bone 39, 724, 2006.
44. Stein, G.S., Lian, J.B., van Wijnen, A.J., Stein, J.L., Montecino, M., Javed, A., Zaidi, S.K., Young, D.W., Choi, J.Y., and Pockwinse, S.M. Runx2 control of organization, assembly and activity of the regulatory machinery for skeletal gene expression Runx2 target genes. Oncogene 23, 4315, 2004.
45. Hung, S.H., Yeh, C.H., Huang, H.T., Wu, P., Ho, M.L., Chen, C.H., Wang, C., Chao, D., and Wang, G.J. Pioglitazone and dexamethasone induce adipogenesis in D1 bone marrow stromal cell line, but not through the peroxisome proliferator-activated receptor-gamma pathway. Life Sci 82, 561, 2008.
46. Pufe, T., Scholz-Ahrens, K.E., Franke, A.T., Petersen, W., Mentlein, R., Varoga, D., Tillmann, B., Schrezenmeir, J., and Glüer, C.C. The role of vascular endothelial growth factor in glucocorticoid-induced bone loss: evaluation in a minipig model. Bone 33, 869, 2003.
47. Li, X., Jin, L., Cui, Q., Wang, G.J., and Balian, G. Steroid effects on osteogenesis through mesenchymal cell gene expression. Osteoporos Int 16, 101, 2005.
48. Esbrit, P., Alvarez-Arroyo, M.V., De Miguel, F., Martén, O., Marténez, M.E., and Caramelo, C. C-terminal parathyroid hormone-related protein increases vascular endothelial growth factor in human osteoblastic cells. J Am Soc Nephrol 11, 1085, 2000.
49. Ardura, J.A., Berruguete, R., Rámila, D., Alvarez-Arroyo, M.V., and Esbrit, P. Parathyroid hormone-related protein interacts with vascular endothelial growth factor to promote fibrogenesis in the obstructed mouse kidney. Am J Physiol Renal Physiol 295, F415, 2008.
50. Jacobsen,K.A.,Al-Aql,Z.S.,Wan, C., Fitch, J.L., Stapleton, S.N., Mason, Z.D., Cole, R.M., Gilbert, S.R., Clemens, T.L., Morgan, E.F., Einhorn, T.A., and Gerstenfeld, L.C. Bone formation during distraction osteogenesis is dependent on both VEGFR1 and VEGFR2 signaling. J Bone Miner Res 23, 596, 2008.
51. Mancini, L., Paul-Clark, M.J., Rosignoli, G., Hannon, R., Martin, J.E., Macintyre, I., and Perretti, M. Calcitonin and prednisolone display antagonistic actions on bone and have synergistic effects in experimental arthritis. Am J Pathol 170, 1018, 2007.
52. Martin, T.J., and Sims, N.A. Osteoclast-derived activity in the coupling of bone formation to resorption. Trends Mol Med 11, 76, 2005.
53. Gu, G., Hentunen, T.A., Nars, M., Härkönen, P.L., and Väänä nen, H.K. Estrogen protects primary osteocytes against glucocorticoid-induced apoptosis. Apoptosis 10, 583, 2005.
54. Jilka, R.L., Weinstein, R.S., Parfitt, A.M., and Manolagas, S.C. Quantifying osteoblast and osteocyte apoptosis: challenges and rewards. J Bone Miner Res 22, 1492, 2007.
55. Villarino, M.E., Sánchez, L.M., Bozal, C.B., and Ubios, A.M. Influence of short-term diabetes on osteocytic lacunae of alveolar bone. A histomorphometric study. Acta Odontol Latinoam 19, 23, 2006.
56. Fenton, A.J., Martin, T.J., and Nicholson, G.C. Long-term culture of disaggregated rat osteoclasts: inhibition of bone resorption and reduction of osteoclast-like cell number by calcitonin and PTHrP [107-139]. J Cell Physiol 155, 1, 1993.
57. Zheng, M.H., McCaughan, H.B., Papadimitriou, J.M., Nicholson, G.C., and Wood, D.J. Tartrate resistant acid phosphatase activity in rat cultured osteoclasts is inhibited by a carboxyl terminal peptide (osteostatin) from parathyroid hormone-related protein. J Cell Biochem 54, 145, 1994